External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul>
<li>Addex is a stub allowing investors to invest in Neurosterix at a lower valuation</li>
<li>Neurosterix, backed by blue-chip VC firms, focuses on targeting muscarinic receptors for psychiatric disorders</li>
<li>Addex transferred assets to Neurosterix in exchange for equity, including an M4 PAM and an mGlu7R NAM</li>
</ul>
<p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>


Addex is a stub allowing investors to invest in Neurosterix at a lower valuation
Neurosterix, backed by blue-chip VC firms, focuses on targeting muscarinic receptors for psychiatric disorders
Addex transferred assets to Neurosterix in exchange for equity, including an M4 PAM and an mGlu7R NAM

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Addex Therapeutics (ADXN.CH) - Wednesday, May 1, 2024

Switzerland

Addex Therapeutics Ltd operates as a biopharmaceutical company. The Company focuses on development allosteric modulators for human health care. Addex Therapeutics serves customers in Switzerland.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Addex Therapeutics (ADXN SW)

Addex Therapeutics (ADXN.CH) - Wednesday, May 1, 2024

Addex is a stub allowing investors to invest in Neurosterix at a lower valuation. Neurosterix, backed by blue-chip VC firms, focuses on targeting...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)